Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ABCB1
REST API REST API
Homo sapiens
ABCB1 is differentially expressed in 283 experiments: 124 organism parts: liver, kidney, ... (122 more);, 184 disease states: normal, lung adenocarcinoma, ... (182 more);, 116 cell types 329 cell lines 25 compound treatments and 74 other conditions.
Synonyms PGY1, CD243, ABC20, GP170, P-gp, CLCS, MDR1
Orthologs Abcb1a (Rattus norvegicus)   E1BS63_CHICK (Gallus gallus)   ENSBTAG00000015666 (Bos taurus)   Abcb1b (Mus musculus)   B2M0T2_BOVIN (Bos taurus)   F1NKZ1_CHICK (Gallus gallus)   Abcb1b (Rattus norvegicus)   Abcb1a (Mus musculus)   CG10226 (Drosophila melanogaster)   Mdr50 (Drosophila melanogaster)   Mdr49 (Drosophila melanogaster)   Mdr65 (Drosophila melanogaster)   STE6 (Saccharomyces cerevisiae)   abcb1 (Xenopus laevis)   NP_001003215.1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term transporter activity, transport, protein binding, nucleoside-triphosphatase activity, membrane, Golgi membrane, ATPase activity, membrane fraction, ATP binding, ATPase activity, coupled to transmembrane movement of substances, G2/M transition of mitotic cell cycle, nucleotide binding, response to drug, apical plasma membrane, integral to membrane, hydrolase activity, xenobiotic-transporting ATPase activity, transmembrane transport, cell surface, intercellular canaliculus, stem cell proliferation
InterPro Term ATPase_AAA+_core, ABC_transporter-like, ABC_transptr_TM_dom, ABC_transporter_type1, ABC_ATPase_put
UniProt Accession B5AK60, B5U2G4, Q6TBL4, P08183, A4D1D2, E7ENX5, E7EWT8, F4ZUT2, F4ZUQ5, F4ZUX9, F4ZUY5, F4ZUV4, F4ZUV0
Gene-Disease Assocation COLCHICINE RESISTANCE, INFLAMMATORY BOWEL DISEASE 13; IBD13
Search EB-eye ENSG00000085563
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-4717, ... (37 experiments)

Factor Value U/D Experiments
MCF-7
1
3
E-GEOD-5823, E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
T47D
2
E-MTAB-62, E-MEXP-440
MCF-10A
2
E-TABM-420, E-GEOD-14990
SW480
2
E-MTAB-37, E-GEOD-18005
T84
2
E-MTAB-37, E-GEOD-1474
HL-60
1
2
E-GEOD-24147, E-GEOD-5258, E-MTAB-37
323 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-TABM-34, ... (54 experiments)

Factor Value U/D Experiments
CD8+ T cell
4
E-AFMX-5, E-GEOD-19069, E-GEOD-6740, E-TABM-145
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
neutrophil
2
E-GEOD-3982, E-GEOD-12662
naive CD4 T cell
1
E-GEOD-22045
T-ALL
1
E-GEOD-19069
110 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-16363, ... (59 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-37, E-GEOD-3726, E-MTAB-62
lung adenocarcinoma
1
3
E-MTAB-37, E-MTAB-62, E-MEXP-231, E-GEOD-2514
acute promyelocytic leukemia
2
E-GEOD-995, E-MTAB-62
breast carcinoma
2
E-GEOD-7307, E-TABM-276
chronic lymphocytic leukemia
2
E-GEOD-6691, E-GEOD-2466
control
2
E-GEOD-8121, E-GEOD-16363
178 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-TABM-782, E-MEXP-2128, E-GEOD-6431, ... (17 experiments)

Factor Value U/D Experiments
control - interferon-gamma
1
E-GEOD-7216
no estradiol
1
E-GEOD-20081
control
1
E-GEOD-3284
flucloxacillin
1
E-MEXP-2128
not specified
1
E-GEOD-20081
placebo
1
E-MEXP-1335
19 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
31
1
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-1140, E-GEOD-860, ... (12 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-MEXP-2359, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-MTAB-69, E-TABM-147, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-MEXP-2340 ... (5 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-TABM-868, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-12773, E-TABM-127, E-MEXP-1446, E-MEXP-1273, E-MEXP-2146, ... (6 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-302, E-GEOD-21653, E-TABM-276, E-GEOD-20194, ... (6 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-GEOD-2466, E-MEXP-2069, ... (35 experiments)

Infection
studied in E-GEOD-2405, E-MEXP-561, E-GEOD-6802

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22229, E-GEOD-1309, E-GEOD-22309, E-GEOD-21750, E-GEOD-1460, ... (8 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

RNAi
studied in E-MEXP-1422, E-MEXP-1509, E-MEXP-101, E-MEXP-548, E-GEOD-3697 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70, E-GEOD-17400

Sex
studied in E-GEOD-19743, E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11886

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-4922

Processing time: 0.466 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM